Stem Cell Research (Mar 2025)
Generation, establishment and characterization of three pluripotent stem cell lines (CVTTHi002-A, CVTTHi003-A and CVTTHi004-A) from primary testicular somatic cells isolated from two prepuberal and one peripuberal Klinefelter Syndrome (47 XXY) patients
- Myriam Martin-Inaraja,
- Irene Romayor,
- Andrea Sáez de Cámara,
- Lara Herrera,
- Ainhoa Palacios,
- Maria Villaverde,
- Silvia Santos,
- Miguel Ángel Vesga,
- Beatriz Barreña,
- Ana María Aransay,
- Juan Anguita,
- Estíbaliz Solorzano,
- María Begoña Prieto,
- Roberto Matorras,
- Cristina Eguizabal
Affiliations
- Myriam Martin-Inaraja
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
- Irene Romayor
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Andrea Sáez de Cámara
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
- Lara Herrera
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Ainhoa Palacios
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
- Maria Villaverde
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain
- Silvia Santos
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Miguel Ángel Vesga
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Beatriz Barreña
- Genetics Unit, Hospital de Basurto, Bilbao, Spain
- Ana María Aransay
- Genomic Analysis Platform, CIC Biogune-BRTA, Derio 48160, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid 28029, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- Juan Anguita
- Inflammation and Macrophage Plasticity Laboratory, CIC bioGUNE-BRTA (Basque Research and Technology Alliance), Derio 48160, Spain; Ikerbasque, Basque Foundation for Science, Bilbao 48013, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Estíbaliz Solorzano
- Biobizkaia Health Research Institute. Cruces University Hospital, Pediatric Surgery Department, Barakaldo, Spain
- María Begoña Prieto
- Biobizkaia Health Research Institute. Cruces University Hospital, Department of Obstetrics and Gynecology, Human Reproduction Unit, Barakaldo 48903-Basque Country University. IVI Bilbao, IVIRMA, Leioa, Vizcaya, Spain
- Roberto Matorras
- Biobizkaia Health Research Institute. Cruces University Hospital, Department of Obstetrics and Gynecology, Human Reproduction Unit, Barakaldo 48903-Basque Country University. IVI Bilbao, IVIRMA, Leioa, Vizcaya, Spain
- Cristina Eguizabal
- Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RD24/0014/0025), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Corresponding author: Advanced Therapies Unit, Basque Centre for Blood Transfusion and Human Tissues, Barrio Labeaga 46A, Galdakao 48960, Spain; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain. Tel.: +34 944007151; Fax: +34 944007160 (C. Eguizabal).
- DOI
- https://doi.org/10.1016/j.scr.2025.103657
- Journal volume & issue
-
Vol. 83
p. 103657
Abstract
Klinefelter Syndrome (KS) is an aneuploid genetic condition in males characterized by at least one additional copy of the X chromosome. Due to fibrotic degeneration of the testis, these patients suffer infertility in the future. The pathogenic mechanism by which this occurs is still not well known. Here, we establish three Induced Pluripotent Stem cell (iPSC) lines derived from prepuberal and peripuberal KS patient’s testicular somatic cells. These could be the first steps towards the creation of an in vitro platform to analyze the molecular mechanisms underlying pathophysiology of the testes in KS patients.
